Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 13/20 | 0.53 |
| ▸ | CDK2 | P24941 | 13/20 | 0.53 |
| ▸ | CCNB1 | P14635 | 10/20 | 0.53 |
| ▸ | CCNE1 | P24864 | 4/20 | 0.53 |
| ▸ | CDK4 | P11802 | 1/20 | 0.53 |
| ▸ | CCND1 | P24385 | 1/20 | 0.53 |
| ▸ | CDK5 | Q00535 | 5/20 | 0.49 |
| ▸ | CSNK2A1 | P68400 | 5/20 | 0.49 |
| ▸ | JAK3 | P52333 | 4/20 | 0.49 |
| ▸ | EGFR | P00533 | 4/20 | 0.49 |
| ▸ | AURKA | O14965 | 3/20 | 0.49 |
| ▸ | DCLK1 | O15075 | 3/20 | 0.49 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.49 |
| ▸ | JAK2 | O60674 | 3/20 | 0.49 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.49 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.49 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.49 |
| ▸ | PRKCG | P05129 | 3/20 | 0.49 |
| ▸ | LCK | P06239 | 3/20 | 0.49 |
| ▸ | FYN | P06241 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11295987 | 0.87 | CDK1 (0.69) | CDK1CDK2CCNB1CCNE1CDK4 | |
| SCHEMBL2438172 | 0.86 | AURKB (0.52) | CDK1CDK2CCNB1CCNE1CDK4 | |
| SCHEMBL11295139 | 0.84 | BMPR2 (0.53) | CDK1CDK2CCNB1CCNE1CDK4 | |
| SCHEMBL11298825 | 0.84 | BMPR2 (0.42) | CDK1CDK2CCNB1CCNE1CDK4 | |
| SCHEMBL11302036 | 0.83 | MAP3K5 (0.57) | CDK1CDK2CCNB1CCNE1CDK4 | |
| SCHEMBL2433277 | 0.82 | BMPR2 (0.41) | CDK1CDK2CCNB1CCNE1CDK4 | |
| SCHEMBL11294980 | 0.81 | CDK2 (0.52) | CDK1CDK2CCNB1CCNE1CDK4 | |
| SCHEMBL11295399 | 0.80 | CDK1 (0.52) | CDK1CDK2CCNB1CCNE1CDK4 | |
| SCHEMBL11292973 | 0.80 | CDK2 (0.48) | CDK1CDK2CCNB1CCNE1CDK4 | |
| SCHEMBL11296005 | 0.80 | CDK1 (0.51) | CDK1CDK2CCNB1CCNE1CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288400-B2 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288400-B2 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288400-B2 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-10-16 | — | — | US | disclosed |
| US-20120183577-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120183577-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120183577-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-19 | — | — | US | disclosed |
| US-8017619-B2 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-09-13 | — | — | US | disclosed |
| US-8017619-B2 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-09-13 | — | — | US | disclosed |
| US-8017619-B2 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-09-13 | — | — | US | disclosed |
| US-20100280026-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-11-04 | — | — | US | disclosed |
| US-20100280026-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-11-04 | — | — | US | disclosed |
| US-20100280026-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-11-04 | — | — | US | disclosed |
| US-7700609-B2 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-20 | — | — | US | disclosed |
| US-7700609-B2 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-20 | — | — | US | disclosed |
| US-7700609-B2 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-20 | — | — | US | disclosed |
| EP-1692140-B1 | COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMA (US) | 2009-12-09 | — | — | EP | disclosed |
| US-20050148603-A1 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2005-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280026-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES | MAP3K20, MAP3K1, MAP3K6 | CDK1 73/4885CDK2 65/4885CCNB1 967/4885 |
| US-20050148603-A1 | Compositions useful as inhibitors of protein kinases | MAP3K20, MAP3K1, MAP3K6 | CDK1 73/4885CDK2 65/4885CCNB1 967/4885 |
| US-20120183577-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES | MAP3K20, MAP3K1, MAP3K6 | CDK1 73/4885CDK2 65/4885CCNB1 967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.